KPIs & Operating Metrics(New)

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Moderna (MRNA) Preferred Shares Issued (2018)

Moderna (MRNA) has disclosed Preferred Shares Issued for 1 consecutive years, with $111.6 million as the latest value for Q2 2018.

For Q2 2018, Preferred Shares Issued changed N/A year-over-year to $111.6 million; the TTM value through Mar 2019 reached $111.6 million, changed N/A, while the annual FY2018 figure was $661.1 million, N/A changed from the prior year.
Preferred Shares Issued hit $111.6 million in Q2 2018 for Moderna, down from $549.5 million in the prior quarter.
Across five years, Preferred Shares Issued topped out at $549.5 million in Q1 2018 and bottomed at $111.6 million in Q2 2018.